Pfizer, GSK and Moderna execs remain optimistic about RSV vaccines despite CDC blowback

The first three RSV vaccines to hit the market should’ve been home runs for Pfizer, GSK and Moderna, but new CDC guidelines may unexpectedly keep the ball in the park. Executives at the pharma giants are trying to look on the bright side.